PCSK9 and atherosclerosis: Current guidelines emphasize on considering addition of non-statins including ezetimibe or a PCSK9 inhibitor to maximally tolerated statin therapy, in very high-risk ASCVD patients with LDL-C levels of ≥ 70mg/dL [18].